Zacks: Analysts Anticipate Adamis Pharmaceuticals Corp (ADMP) Will Post Earnings of -$0.15 Per Share

Brokerages expect Adamis Pharmaceuticals Corp (NASDAQ:ADMP) to post earnings per share of ($0.15) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Adamis Pharmaceuticals’ earnings. The highest EPS estimate is ($0.14) and the lowest is ($0.15). The company is expected to announce its next earnings results on Thursday, March 29th.

According to Zacks, analysts expect that Adamis Pharmaceuticals will report full-year earnings of ($0.79) per share for the current fiscal year, with EPS estimates ranging from ($0.79) to ($0.78). For the next year, analysts anticipate that the firm will post earnings of ($0.64) per share, with EPS estimates ranging from ($0.67) to ($0.60). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Adamis Pharmaceuticals.

A number of equities research analysts have weighed in on ADMP shares. Maxim Group set a $14.00 price target on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, December 5th. B. Riley set a $10.00 price target on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, November 30th. Zacks Investment Research upgraded shares of Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. Finally, ValuEngine cut shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 30th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $10.33.

Several institutional investors and hedge funds have recently made changes to their positions in the business. B. Riley Financial Inc. acquired a new stake in shares of Adamis Pharmaceuticals during the fourth quarter valued at about $1,022,000. Virtu Financial LLC acquired a new stake in shares of Adamis Pharmaceuticals during the fourth quarter valued at about $442,000. Wells Fargo & Company MN increased its position in shares of Adamis Pharmaceuticals by 1,050.3% during the fourth quarter. Wells Fargo & Company MN now owns 28,182 shares of the specialty pharmaceutical company’s stock valued at $124,000 after acquiring an additional 25,732 shares during the last quarter. EAM Investors LLC increased its position in shares of Adamis Pharmaceuticals by 58.3% during the third quarter. EAM Investors LLC now owns 371,732 shares of the specialty pharmaceutical company’s stock valued at $1,942,000 after acquiring an additional 136,970 shares during the last quarter. Finally, Granite Investment Partners LLC acquired a new stake in shares of Adamis Pharmaceuticals during the third quarter valued at about $457,000. Institutional investors and hedge funds own 16.54% of the company’s stock.

Adamis Pharmaceuticals (NASDAQ ADMP) opened at $3.60 on Wednesday. The company has a quick ratio of 3.79, a current ratio of 3.93 and a debt-to-equity ratio of 0.06. Adamis Pharmaceuticals has a 52 week low of $3.20 and a 52 week high of $6.45.

WARNING: “Zacks: Analysts Anticipate Adamis Pharmaceuticals Corp (ADMP) Will Post Earnings of -$0.15 Per Share” was published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/14/zacks-analysts-anticipate-adamis-pharmaceuticals-corp-admp-will-post-earnings-of-0-15-per-share.html.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Get a free copy of the Zacks research report on Adamis Pharmaceuticals (ADMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply